az1 — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T7685	USP25/28 inhibitor AZ1	AZ1	DUB
	USP25/28 inhibitor AZ1 (AZ1) (AZ1) is an inhibitor of ubiquitin specific protease (USP) 25/28		DUB
T11876	LpxH-IN-AZ1		Antibacterial
	LpxH-IN-AZ1 is a potent inhibitor of the UDP-2,3-diacylglucosamine pyrophosphate hydrolase, LpxH, and sulfonylpiperazine compounds.LpxH-IN-AZ1 exhibits antimicrobial activity and inhibits Klebsiella pneumoniae with an IC...		Antibacterial
T68668	AZ-1
	AZ-1 is an inducer of ABCA1 and apoE. It enhances ABCA1 activity and decreases P2X7 receptor activity. AZ-1 activates endogenous LXR signaling but shows no direct LXRα or LXRβ agonist activity.
T9552	BAZ1A-IN-1		Epigenetic Reader Domain
	BAZ1A-IN-1 is a potent BAZ1A inhibitor with the KD value of 0.52 μM for the BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-survival activity against cancer cell lines with high BAZ1A expression, but weak or no activity ag...		Epigenetic Reader Domain
T14366	AZ10606120 dihydrochloride		P2X Receptor
	AZ10606120 dihydrochloride is a selectable, potent, high-affinity receptor antagonist with K D values of 1.4 and 19 nM at human and rat P2X 7 receptors, respectively. AZ10606120 dihydrochloride inhibits tumor growth and ...		P2X Receptor
T9650	AZ12672857		Src , Ephrin Receptor
	AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM. AZ12672857 inhibits cell proliferation of Src transfected 3T3 cells with IC50 of 2 nM and autophosphorylation of EphB4 in transfected CHO-K1 cells with IC50 of 9 n...		Src , Ephrin Receptor
T26701	AZ12216052	AZ 12216052,AZ-12216052
	AZ12216052 is an activator of mGluR II and III.
T26704	AZ13705339	AZ-13705339,AZ 13705339	PAK
	AZ13705339 is an effective inhibitor of PAK1 with an IC50 of 0.33 nM and a Kd of 0.28 nM. AZ13705339 binds PAK2 with a Kd of 0.32 nM. AZ13705339 can be used in studies about cancers.		PAK
T14367	AZ1495		IRAK , CDK , Haspin Kinase
	AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity in treatment of mutant MYD88L265P diffu...		IRAK , CDK , Haspin Kinase
T6257	AZ191		DYRK
	AZ191（IC50 of 17 nM） is an effective and specific DYRK1B inhibitor. The specificity of AZ191 for DYRK1B is about 5- and 110-fold greater over DYRK1A and DYRK2, respectively.		DYRK
T9461	AZ194		Sodium Channel
	CRMP2-Ubc9-NaV1.7 inhibitor 194, is a CRMP2-Ubc9-NaV1.7 inhibitor.		Sodium Channel
T63976	AZ13824374
	AZ13824374 is a potent and selective ATAD2 inhibitor with anti-proliferative effects in breast cancer. pIC50 values for AZ13824374 against ATAD2 in the ATAD2 FRET and ATAD2 NanoBRET assays were 8.2 and 6.2, respectively.
T63968	AZ14145845
	AZ14145845 is an in vivo potent and highly selective type I1/2 Mer/Axl bispecific kinase inhibitor.
T10426	AZ12601011		ALK
	AZ12601011 is a highly potent and selective inhibitor of the TGFBR1 kinase, administered orally. It displays an IC50 of 18 nM and a Kd of 2.9 nM. By selectively targeting ALK4, TGFBR1, and ALK7, AZ12601011 effectively in...		ALK
T30244	AZ12419304	GTPL7734,GTPL 7734,AZ-12419304,GTPL-7734
	AZ12419304, also known as GTPL7734, is a bioactive chemical.
T26700	AZ11657312 Free Base	AZ-11657312,AZ11657312,AZ 11657312
	AZ11657312 is a P2X7 receptor antagonist.
T26703	AZ13483342	AZ-13483342,AZ 13483342
	AZ13483342 is an antagonist of the melanin concentrating hormone receptor 1 (MCH1) with a potential diabetes therapeutic activity.
T18310	AZ1508	MC-Lys-MMETA	Others
	AZ1508, a tubulin inhibitor[1], serves as a drug-linker conjugate for antibody-drug conjugates (ADC) targeting breast and stomach cancer treatment.		Others
T26699	AZ10397767	AZ 10397767,AZ-10397767
	AZ10397767 is a potent CXCR2 antagonist (IC50 = 1 nM). AZ10397767 significantly reduced the numbers of infiltrating neutrophils into both in vitro and in vivo tumor models.
T70312	AZ1366
	AZ1366 is a potent tankyrase inhibitor that enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Combination AZ1366 and irinotecan achieved greater anti-tumor effects compare...